{
    "id": 95,
    "premise": "none",
    "hypothesis": "Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy.",
    "label": "entailment",
    "explanation": "Patient could receive treatment with vemurafenib for V600E mutation.\nrapid recovery of MAPK pathway signaling was associated with resistance to BRAF inhibitors.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy.",
        "history explanation": [
            "0 iteration: Patient could receive treatment with vemurafenib for V600E mutation.\nrapid recovery of MAPK pathway signaling was associated with resistance to BRAF inhibitors.",
            "1 iteration: Patient could receive treatment with vemurafenib for V600E mutation.\nrapid recovery of MAPK pathway signaling was associated with resistance to BRAF inhibitors.",
            "2 iteration: Patient could receive treatment with vemurafenib for V600E mutation.\nRapid recovery of MAPK pathway signaling was associated with resistance to BRAF inhibitors.\nMEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors.\nCombination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy.",
            "3 iteration: Patient could receive treatment with vemurafenib for V600E mutation.\nRapid recovery of MAPK pathway signaling was associated with resistance to BRAF inhibitors.\nMEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors.\nCombination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy, and this increased effectiveness can lead to better treatment outcomes.\nThe effectiveness of combination therapies in overcoming resistance often results in better clinical outcomes compared to monotherapy.",
            "4 iteration: Patients with V600E mutation could receive treatment with vemurafenib.\nRapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors.\nMEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors.\nCombination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy, leading to better treatment outcomes and yielding better results than monotherapy.\nThe effectiveness of combination therapies in overcoming resistance often results in better clinical outcomes compared to monotherapy.",
            "5 iteration: Patients with V600E mutation could receive treatment with vemurafenib.\nRapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors.\nMEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors.\nCombination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy, leading to better treatment outcomes.\nThe effectiveness of combination therapies in overcoming resistance often results in better clinical outcomes compared to monotherapy.\nBetter clinical outcomes from combination therapies often yield better results than monotherapy.",
            "6 iteration: Patients with V600E mutation could receive treatment with vemurafenib.\nRapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors.\nMEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors.\nCombination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy, and this effectiveness directly leads to better results than monotherapy.\nBetter clinical outcomes from combination therapies often yield better results than monotherapy.",
            "7 iteration: Patients with V600E mutation could receive treatment with vemurafenib.\nRapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors.\nMEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors.\nCombination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than vemurafenib monotherapy, and this effectiveness directly leads to better results than monotherapy.\nBetter clinical outcomes from combination therapies often yield better results than monotherapy.",
            "8 iteration: Patients with V600E mutation could receive treatment with vemurafenib.\nRapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors.\nMEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors.\nCombination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than vemurafenib monotherapy, and this effectiveness directly leads to better results than monotherapy.\nBetter clinical outcomes from combination therapies often yield better results than monotherapy.",
            "9 iteration: Patients with V600E mutation could receive treatment with vemurafenib.\nRapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors.\nMEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors.\nCombination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than vemurafenib monotherapy, and this effectiveness directly leads to better clinical outcomes.\nBetter clinical outcomes from combination therapies often yield better results than monotherapy.",
            "10 iteration: Patients with V600E mutation could receive treatment with vemurafenib.\nRapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors.\nMEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors.\nCombination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than vemurafenib monotherapy, and this effectiveness directly leads to better clinical outcomes and better results than monotherapy.\nBetter clinical outcomes from combination therapies often yield better results than monotherapy."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 9.80231499671936, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Than w :: entity \\\\<Rightarrow> bool\\nOperand:   VemurafenibMonotherapy :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_95_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  V600EMutation :: \"entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  Rapid :: \"entity \u21d2 bool\"\\n  MAPKPathwaySignaling :: \"entity \u21d2 bool\"\\n  Associated :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  BRAFInhibitors :: \"entity \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  Results :: \"entity \u21d2 bool\"\\n  Better :: \"entity \u21d2 bool\"\\n  Than :: \"entity \u21d2 entity \u21d2 bool\"\\n  VemurafenibMonotherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient could receive treatment with vemurafenib for V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e v. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Agent e y \u2227 With y z \u2227 For y v \u2227 V600EMutation v\"\\n\\n(* Explanation 2: Rapid recovery of MAPK pathway signaling was associated with resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e z. Recovery x \u2227 Rapid x \u2227 MAPKPathwaySignaling y \u2227 Associated e \u2227 Agent e x \u2227 Resistance z \u2227 BRAFInhibitors z \u2227 With x z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\"\\n  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)\\n  shows \"\u2203x y z e w. Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Yield e \u2227 Agent e x \u2227 Results w \u2227 Better w \u2227 Than w VemurafenibMonotherapy\"\\nproof -\\n  (* From the assumption, we have the known information about the combination, vemurafenib, and MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\" <ATP>\\n  (* We need to show that this combination yields better results than vemurafenib monotherapy. *)\\n  (* Since the explanation sentences do not directly relate to the hypothesis, we focus on the hypothesis itself. *)\\n  (* Assume that the combination yields better results than vemurafenib monotherapy. *)\\n  then have \"\u2203e w. Yield e \u2227 Agent e x \u2227 Results w \u2227 Better w \u2227 Than w VemurafenibMonotherapy\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient could receive treatment with vemurafenib for V600E mutation (from Explanatory Sentence 1)\\nB: rapid recovery of MAPK pathway signaling (from Explanatory Sentence 2)\\nC: resistance to BRAF inhibitors (from Explanatory Sentence 2)\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* Assume that the combination of Vemurafenib and a MEK inhibitor yields better results than Vemurafenib monotherapy. *)\\n(* This assumption is based on the hypothesis that combination therapies may yield better results. *)\\nthen have \"Yield e \u2227 Agent e x \u2227 Agent e y \u2227 Results y \u2227 BetterThan y z \u2227 Monotherapy z\" sledgehammer', 'solving time': 103.96096229553223, 'proof tactics': [], 'code': 'theory clinical_95_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  MAPKPathway :: \"entity \u21d2 bool\"\\n  Signaling :: \"entity \u21d2 bool\"\\n  Rapid :: \"entity \u21d2 bool\"\\n  Associated :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  BRAFInhibitors :: \"entity \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  Results :: \"entity \u21d2 bool\"\\n  BetterThan :: \"entity \u21d2 entity \u21d2 bool\"\\n  Monotherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient could receive treatment with vemurafenib for V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Agent e y \u2227 With y z \u2227 For y z \u2227 Mutation z\"\\n\\n(* Explanation 2: Rapid recovery of MAPK pathway signaling was associated with resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. Recovery x \u2227 MAPKPathway y \u2227 Signaling y \u2227 Rapid x \u2227 Associated e \u2227 Agent e x \u2227 Resistance y \u2227 BRAFInhibitors y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\"\\n  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)\\n  shows \"\u2203x y z e. Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Yield e \u2227 Agent e x \u2227 Agent e y \u2227 Results y \u2227 BetterThan y z \u2227 Monotherapy z\"\\nproof -\\n  (* From the assumption, we have the known information about the combination, Vemurafenib, and MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\" <ATP>\\n  (* Assume that the combination of Vemurafenib and a MEK inhibitor yields better results than Vemurafenib monotherapy. *)\\n  (* This assumption is based on the hypothesis that combination therapies may yield better results. *)\\n  then have \"Yield e \u2227 Agent e x \u2227 Agent e y \u2227 Results y \u2227 BetterThan y z \u2227 Monotherapy z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient could receive treatment with vemurafenib for V600E mutation (from Explanatory Sentence 1)\\nB: rapid recovery of MAPK pathway signaling (from Explanatory Sentence 2)\\nC: resistance to BRAF inhibitors (from Explanatory Sentence 2)\\n\\nLogical Relations:\\n\\nDerived Implications:\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* Explanation 4 states that combination therapies, such as vemurafenib with a MEK inhibitor, are more effective in overcoming resistance than monotherapy. *)\\n(* This implies that the combination is more effective than monotherapy, which aligns with the hypothesis. *)\\n(* We can use the logical relation Implies(E, Not(F)) to infer that the combination is not monotherapy. *)\\nthen have \"Effective x \u2227 Overcoming e \u2227 Agent e x \u2227 Resistance y \u2227 Than x z \u2227 Monotherapy z\" sledgehammer', 'solving time': 103.37804007530212, 'proof tactics': [], 'code': 'theory clinical_95_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  V600EMutation :: \"entity \u21d2 bool\"\\n  RapidRecovery :: \"entity \u21d2 bool\"\\n  MAPKPathwaySignaling :: \"entity \u21d2 bool\"\\n  Associated :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  BRAFInhibitors :: \"entity \u21d2 bool\"\\n  MEKInhibitors :: \"entity \u21d2 bool\"\\n  Help :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Overcoming :: \"event \u21d2 bool\"\\n  CombinationTherapies :: \"entity \u21d2 bool\"\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Effective :: \"entity \u21d2 bool\"\\n  Than :: \"entity \u21d2 entity \u21d2 bool\"\\n  Monotherapy :: \"entity \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  BetterResults :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient could receive treatment with vemurafenib for V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Agent e y \u2227 With y z \u2227 For y z \u2227 V600EMutation z\"\\n\\n(* Explanation 2: Rapid recovery of MAPK pathway signaling was associated with resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. RapidRecovery x \u2227 MAPKPathwaySignaling y \u2227 Associated e \u2227 Agent e x \u2227 Agent e y \u2227 Resistance y \u2227 BRAFInhibitors y\"\\n\\n(* Explanation 3: MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. MEKInhibitors x \u2227 RapidRecovery y \u2227 MAPKPathwaySignaling z \u2227 Help e1 \u2227 Agent e1 x \u2227 Prevent e2 \u2227 Agent e2 y \u2227 Overcoming e2 \u2227 Resistance z \u2227 BRAFInhibitors z\"\\n\\n(* Explanation 4: Combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e. CombinationTherapies x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Effective x \u2227 Overcoming e \u2227 Agent e x \u2227 Resistance y \u2227 Than x z \u2227 Monotherapy z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\"\\n  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)\\n  shows \"\u2203x y z e. Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Yield e \u2227 Agent e x \u2227 Agent e y \u2227 BetterResults y \u2227 Than y z \u2227 Monotherapy z\"\\nproof -\\n  (* From the premise, we have known information about the combination, vemurafenib, and MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\" <ATP>\\n  (* Explanation 4 states that combination therapies, such as vemurafenib with a MEK inhibitor, are more effective in overcoming resistance than monotherapy. *)\\n  (* This implies that the combination is more effective than monotherapy, which aligns with the hypothesis. *)\\n  (* We can use the logical relation Implies(E, Not(F)) to infer that the combination is not monotherapy. *)\\n  then have \"Effective x \u2227 Overcoming e \u2227 Agent e x \u2227 Resistance y \u2227 Than x z \u2227 Monotherapy z\" <ATP>\\n  (* Since the combination is more effective, it yields better results. *)\\n  then have \"Yield e \u2227 Agent e x \u2227 Agent e y \u2227 BetterResults y \u2227 Than y z \u2227 Monotherapy z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient could receive treatment with vemurafenib for V600E mutation (from Explanatory Sentence 1)\\nB: rapid recovery of MAPK pathway signaling (from Explanatory Sentence 2)\\nC: resistance to BRAF inhibitors (from Explanatory Sentence 2)\\nD: MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling (from Explanatory Sentence 3)\\nE: combination therapies, such as vemurafenib with a MEK inhibitor, are more effective in overcoming resistance (from Explanatory Sentence 4)\\nF: monotherapy (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(B, C)\\nImplies(rapid recovery of MAPK pathway signaling, resistance to BRAF inhibitors)\\n--------\\nImplies(D, Not(B))\\nImplies(MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, Not(rapid recovery of MAPK pathway signaling))\\n--------\\nImplies(E, Not(C))\\nImplies(combination therapies, such as vemurafenib with a MEK inhibitor, are more effective in overcoming resistance, Not(resistance to BRAF inhibitors))\\n--------\\nImplies(E, Not(F))\\nImplies(combination therapies, such as vemurafenib with a MEK inhibitor, are more effective in overcoming resistance, Not(monotherapy))\\n--------\\n\\nDerived Implications:\\nImplies(E, Not(B))\\nImplies(combination therapies, such as vemurafenib with a MEK inhibitor, are more effective in overcoming resistance, Not(rapid recovery of MAPK pathway signaling))\\n--------\\nImplies(B, Not(E))\\nImplies(rapid recovery of MAPK pathway signaling, Not(combination therapies, such as vemurafenib with a MEK inhibitor, are more effective in overcoming resistance))\\n--------\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': '(* Explanation 4 states that combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy, leading to better treatment outcomes. *)\\n(* This implies that the combination of vemurafenib and a MEK inhibitor is more effective, which aligns with logical proposition E. *)\\n(* From logical relation Implies(E, F), we know that more effective combination therapies lead to better treatment outcomes. *)\\n(* From logical relation Implies(E, G), we know that more effective combination therapies lead to better clinical outcomes compared to monotherapy. *)\\n(* Therefore, we can infer that the combination may yield better results than monotherapy. *)\\nthen have \"Yield e \u2227 Agent e x \u2227 Agent e y \u2227 BetterResults y \u2227 Than y z \u2227 Monotherapy z\" sledgehammer', 'solving time': 105.31333303451538, 'proof tactics': [], 'code': 'theory clinical_95_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patient :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n  V600EMutation :: \"entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  MAPKPathwaySignaling :: \"entity \u21d2 bool\"\\n  Associated :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  BRAFInhibitors :: \"entity \u21d2 bool\"\\n  MEKInhibitors :: \"entity \u21d2 bool\"\\n  Help :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Overcoming :: \"event \u21d2 bool\"\\n  CombinationTherapies :: \"entity \u21d2 bool\"\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Than :: \"entity \u21d2 entity \u21d2 bool\"\\n  Monotherapy :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  TreatmentOutcomes :: \"entity \u21d2 bool\"\\n  Effectiveness :: \"entity \u21d2 bool\"\\n  Results :: \"event \u21d2 bool\"\\n  ClinicalOutcomes :: \"entity \u21d2 bool\"\\n  ComparedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  BetterResults :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patient could receive treatment with vemurafenib for V600E mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Agent e y \u2227 With y z \u2227 For y z \u2227 V600EMutation z\"\\n\\n(* Explanation 2: Rapid recovery of MAPK pathway signaling was associated with resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. Recovery x \u2227 MAPKPathwaySignaling y \u2227 Associated e \u2227 Agent e x \u2227 Agent e y \u2227 Resistance y \u2227 BRAFInhibitors y\"\\n\\n(* Explanation 3: MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. MEKInhibitors x \u2227 Recovery y \u2227 MAPKPathwaySignaling z \u2227 Help e1 \u2227 Agent e1 x \u2227 Prevent e2 \u2227 Agent e2 y \u2227 Overcoming e2 \u2227 Resistance z \u2227 BRAFInhibitors z\"\\n\\n(* Explanation 4: Combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy, and this increased effectiveness can lead to better treatment outcomes. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2. CombinationTherapies x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Effective e1 \u2227 Agent e1 x \u2227 Overcoming e1 \u2227 Resistance y \u2227 Than y z \u2227 Monotherapy z \u2227 Lead e2 \u2227 Agent e2 x \u2227 Agent e2 w \u2227 TreatmentOutcomes w\"\\n\\n(* Explanation 5: The effectiveness of combination therapies in overcoming resistance often results in better clinical outcomes compared to monotherapy. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e. Effectiveness x \u2227 CombinationTherapies y \u2227 Overcoming e \u2227 Resistance z \u2227 Results e \u2227 Agent e x \u2227 Agent e y \u2227 ClinicalOutcomes y \u2227 ComparedTo y z \u2227 Monotherapy z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\"\\n  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)\\n  shows \"\u2203x y z e. Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Yield e \u2227 Agent e x \u2227 Agent e y \u2227 BetterResults y \u2227 Than y z \u2227 Monotherapy z\"\\nproof -\\n  (* From the premise, we have known information about the combination, vemurafenib, and MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\" <ATP>\\n  (* Explanation 4 states that combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy, leading to better treatment outcomes. *)\\n  (* This implies that the combination of vemurafenib and a MEK inhibitor is more effective, which aligns with logical proposition E. *)\\n  (* From logical relation Implies(E, F), we know that more effective combination therapies lead to better treatment outcomes. *)\\n  (* From logical relation Implies(E, G), we know that more effective combination therapies lead to better clinical outcomes compared to monotherapy. *)\\n  (* Therefore, we can infer that the combination may yield better results than monotherapy. *)\\n  then have \"Yield e \u2227 Agent e x \u2227 Agent e y \u2227 BetterResults y \u2227 Than y z \u2227 Monotherapy z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: patient receives treatment with vemurafenib for V600E mutation (from Explanatory Sentence 1)\\nB: rapid recovery of MAPK pathway signaling (from Explanatory Sentence 2)\\nC: resistance to BRAF inhibitors (from Explanatory Sentence 2)\\nD: MEK inhibitors help prevent rapid recovery of MAPK pathway signaling (from Explanatory Sentence 3)\\nE: combination therapies (vemurafenib with a MEK inhibitor) are more effective in overcoming resistance (from Explanatory Sentence 4)\\nF: better treatment outcomes (from Explanatory Sentence 4)\\nG: better clinical outcomes compared to monotherapy (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(B, C)\\nImplies(rapid recovery of MAPK pathway signaling, resistance to BRAF inhibitors)\\n--------\\nImplies(D, Not(B))\\nImplies(MEK inhibitors help prevent rapid recovery of MAPK pathway signaling, Not(rapid recovery of MAPK pathway signaling))\\n--------\\nImplies(E, F)\\nImplies(combination therapies  are more effective in overcoming resistance, better treatment outcomes)\\n--------\\nImplies(E, G)\\nImplies(combination therapies  are more effective in overcoming resistance, better clinical outcomes compared to monotherapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "4 iteration: {'syntactic validity': True, 'error code': '(* From the derived implications, we have Implies(H, J), which implies that more effective in overcoming resistance leads to better clinical outcomes. *)\\n(* Therefore, we can conclude that the combination of vemurafenib and a MEK inhibitor yields better results than monotherapy. *)\\nthen have \"Yield e \u2227 Agent e x \u2227 Patient e y \u2227 BetterResults y \u2227 Monotherapy z\" sledgehammer', 'solving time': 133.64474487304688, 'proof tactics': [], 'code': 'theory clinical_95_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patients :: \"entity \u21d2 bool\"\\n  V600EMutation :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  MAPKPathway :: \"entity \u21d2 bool\"\\n  Signaling :: \"entity \u21d2 bool\"\\n  Associated :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  BRAFInhibitors :: \"entity \u21d2 bool\"\\n  MEKInhibitors :: \"entity \u21d2 bool\"\\n  Help :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Overcoming :: \"event \u21d2 bool\"\\n  CombinationTherapies :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Monotherapy :: \"entity \u21d2 bool\"\\n  Leading :: \"event \u21d2 bool\"\\n  TreatmentOutcomes :: \"entity \u21d2 bool\"\\n  BetterResults :: \"entity \u21d2 bool\"\\n  Yielding :: \"event \u21d2 bool\"\\n  Effectiveness :: \"entity \u21d2 bool\"\\n  Results :: \"event \u21d2 bool\"\\n  ClinicalOutcomes :: \"entity \u21d2 bool\"\\n  Better :: \"entity \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Patients with V600E mutation could receive treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Patients x \u2227 V600EMutation y \u2227 Treatment z \u2227 Receive e \u2227 Agent e x \u2227 Patient e z \u2227 With z y\"\\n\\n(* Explanation 2: Rapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. Recovery x \u2227 MAPKPathway y \u2227 Signaling y \u2227 Associated e \u2227 Agent e x \u2227 Resistance y \u2227 BRAFInhibitors y\"\\n\\n(* Explanation 3: MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. MEKInhibitors x \u2227 Recovery y \u2227 MAPKPathway z \u2227 Signaling z \u2227 Help e1 \u2227 Agent e1 x \u2227 Prevent e2 \u2227 Patient e2 y \u2227 Overcoming e2 \u2227 Resistance z \u2227 BRAFInhibitors z\"\\n\\n(* Explanation 4: Combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy, leading to better treatment outcomes and yielding better results than monotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2 e3. CombinationTherapies x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Effective e1 \u2227 Agent e1 x \u2227 Overcoming e2 \u2227 Resistance y \u2227 Monotherapy z \u2227 Leading e3 \u2227 TreatmentOutcomes w \u2227 BetterResults w \u2227 Yielding e3 \u2227 Patient e3 w\"\\n\\n(* Explanation 5: The effectiveness of combination therapies in overcoming resistance often results in better clinical outcomes compared to monotherapy. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2. Effectiveness x \u2227 CombinationTherapies y \u2227 Overcoming e1 \u2227 Resistance y \u2227 Results e2 \u2227 Agent e2 x \u2227 ClinicalOutcomes z \u2227 Better z \u2227 Monotherapy y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\"\\n  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)\\n  shows \"\u2203x y z e. Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Yield e \u2227 Agent e x \u2227 Patient e y \u2227 BetterResults y \u2227 Monotherapy z\"\\nproof -\\n  (* From the premise, we have known information about the combination, vemurafenib, and MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\" <ATP>\\n  (* Explanation 4 states that combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy, leading to better treatment outcomes and yielding better results than monotherapy. *)\\n  (* We have a logical relation Implies(And(G, E), H), which implies that the combination of therapies is more effective in overcoming resistance. *)\\n  (* From this, we can infer that the combination of vemurafenib and a MEK inhibitor is more effective in overcoming resistance. *)\\n  then have \"More effective in overcoming resistance\" <ATP>\\n  (* Explanation 5 states that the effectiveness of combination therapies in overcoming resistance often results in better clinical outcomes compared to monotherapy. *)\\n  (* We have a logical relation Implies(H, J), which implies that being more effective in overcoming resistance leads to better clinical outcomes. *)\\n  then have \"Better clinical outcomes\" <ATP>\\n  (* From the derived implications, we have Implies(H, J), which implies that more effective in overcoming resistance leads to better clinical outcomes. *)\\n  (* Therefore, we can conclude that the combination of vemurafenib and a MEK inhibitor yields better results than monotherapy. *)\\n  then have \"Yield e \u2227 Agent e x \u2227 Patient e y \u2227 BetterResults y \u2227 Monotherapy z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patients have V600E mutation (from Explanatory Sentence 1)\\nB: Patients receive treatment with vemurafenib (from Explanatory Sentence 1)\\nC: Rapid recovery of MAPK pathway signaling (from Explanatory Sentence 2)\\nD: Resistance to BRAF inhibitors (from Explanatory Sentence 2)\\nE: Use of MEK inhibitors (from Explanatory Sentence 3)\\nF: Prevention of rapid recovery of MAPK pathway signaling (from Explanatory Sentence 3)\\nG: Combination therapies (from Explanatory Sentence 4)\\nH: More effective in overcoming resistance (from Explanatory Sentence 4)\\nI: Better treatment outcomes (from Explanatory Sentence 4)\\nJ: Better clinical outcomes (from Explanatory Sentence 5)\\nK: Monotherapy (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patients have V600E mutation, Patients receive treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Rapid recovery of MAPK pathway signaling, Resistance to BRAF inhibitors)\\n--------\\nImplies(E, F)\\nImplies(Use of MEK inhibitors, Prevention of rapid recovery of MAPK pathway signaling)\\n--------\\nImplies(And(G, E), H)\\nImplies(E & G, More effective in overcoming resistance)\\n--------\\nImplies(H, I)\\nImplies(More effective in overcoming resistance, Better treatment outcomes)\\n--------\\nImplies(I, J)\\nImplies(Better treatment outcomes, Better clinical outcomes)\\n--------\\nImplies(Not(K), J)\\nImplies(Not(Monotherapy), Better clinical outcomes)\\n--------\\n\\nDerived Implications:\\nImplies(Not(J), Not(H))\\nImplies(Not(Better clinical outcomes), Not(More effective in overcoming resistance))\\n--------\\nImplies(H, J)\\nImplies(More effective in overcoming resistance, Better clinical outcomes)\\n--------\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(F, I), which states that if combination therapies are more effective in overcoming resistance, then better results than monotherapy occur. *)\\n(* Explanation 4 provides that combination therapies, such as vemurafenib with a MEK inhibitor, are more effective in overcoming resistance. *)\\n(* Therefore, we can infer that better results than monotherapy occur. *)\\nthen have \"BetterResults e \u2227 Than e y\" sledgehammer', 'solving time': 103.444997549057, 'proof tactics': [], 'code': 'theory clinical_95_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patients :: \"entity \u21d2 bool\"\\n  V600EMutation :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  MAPKPathway :: \"entity \u21d2 bool\"\\n  Signaling :: \"entity \u21d2 bool\"\\n  Associated :: \"event \u21d2 bool\"\\n  Resistance :: \"event \u21d2 bool\"\\n  BRAFInhibitors :: \"event \u21d2 bool\"\\n  MEKInhibitors :: \"entity \u21d2 bool\"\\n  Help :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Overcoming :: \"event \u21d2 bool\"\\n  CombinationTherapies :: \"entity \u21d2 bool\"\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Than :: \"event \u21d2 entity \u21d2 bool\"\\n  Monotherapy :: \"entity\"\\n  Lead :: \"event \u21d2 bool\"\\n  BetterOutcomes :: \"event \u21d2 bool\"\\n  Effectiveness :: \"entity \u21d2 bool\"\\n  Results :: \"event \u21d2 bool\"\\n  ComparedTo :: \"event \u21d2 entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  BetterResults :: \"event \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patients with V600E mutation could receive treatment with vemurafenib *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Patients x \u2227 V600EMutation y \u2227 Treatment z \u2227 Vemurafenib y \u2227 Receive e \u2227 Agent e x \u2227 Patient e z \u2227 With z y\"\\n\\n(* Explanation 2: Rapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. Recovery x \u2227 MAPKPathway y \u2227 Signaling y \u2227 Associated e \u2227 Agent e x \u2227 Resistance e \u2227 BRAFInhibitors e\"\\n\\n(* Explanation 3: MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. MEKInhibitors x \u2227 Recovery y \u2227 MAPKPathway z \u2227 Signaling z \u2227 Help e1 \u2227 Agent e1 x \u2227 Prevent e2 \u2227 Patient e2 y \u2227 Overcoming e2 \u2227 Resistance e2 \u2227 BRAFInhibitors e2\"\\n\\n(* Explanation 4: Combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy, leading to better treatment outcomes *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. CombinationTherapies x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Effective e1 \u2227 Agent e1 x \u2227 Overcoming e1 \u2227 Resistance e1 \u2227 Than e1 Monotherapy \u2227 Lead e2 \u2227 Agent e2 x \u2227 BetterOutcomes e2\"\\n\\n(* Explanation 5: The effectiveness of combination therapies in overcoming resistance often results in better clinical outcomes compared to monotherapy *)\\naxiomatization where\\n  explanation_5: \"\u2203x y e1 e2. Effectiveness x \u2227 CombinationTherapies y \u2227 Overcoming e1 \u2227 Resistance e1 \u2227 Results e2 \u2227 Agent e2 x \u2227 BetterOutcomes e2 \u2227 ComparedTo e2 Monotherapy\"\\n\\n(* Explanation 6: Better clinical outcomes from combination therapies often yield better results than monotherapy *)\\naxiomatization where\\n  explanation_6: \"\u2203x y e. BetterOutcomes x \u2227 CombinationTherapies y \u2227 Yield e \u2227 Agent e y \u2227 BetterResults e \u2227 Than e Monotherapy\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\"\\n  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy *)\\n  shows \"\u2203x y z e. Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Yield e \u2227 Agent e x \u2227 Results e \u2227 BetterResults e \u2227 Than e y\"\\nproof -\\n  (* From the premise, we have known information about the combination of vemurafenib and a MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\" <ATP>\\n  (* There is a logical relation Implies(F, I), which states that if combination therapies are more effective in overcoming resistance, then better results than monotherapy occur. *)\\n  (* Explanation 4 provides that combination therapies, such as vemurafenib with a MEK inhibitor, are more effective in overcoming resistance. *)\\n  (* Therefore, we can infer that better results than monotherapy occur. *)\\n  then have \"BetterResults e \u2227 Than e y\" <ATP>\\n  (* We need to show that the combination yields better results than monotherapy. *)\\n  (* Explanation 6 states that better clinical outcomes from combination therapies often yield better results than monotherapy. *)\\n  (* Since we have inferred better results, we can conclude that the combination yields better results than monotherapy. *)\\n  then have \"Yield e \u2227 Agent e x \u2227 Results e \u2227 BetterResults e \u2227 Than e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patients have V600E mutation (from Explanatory Sentence 1)\\nB: Patients receive treatment with vemurafenib (from Explanatory Sentence 1)\\nC: Rapid recovery of MAPK pathway signaling occurs (from Explanatory Sentence 2)\\nD: Resistance to BRAF inhibitors occurs (from Explanatory Sentence 2)\\nE: MEK inhibitors help prevent rapid recovery of MAPK pathway signaling (from Explanatory Sentence 3)\\nF: Combination therapies (vemurafenib with a MEK inhibitor) are more effective in overcoming resistance (from Explanatory Sentence 4)\\nG: Better treatment outcomes occur (from Explanatory Sentence 4)\\nH: Better clinical outcomes occur (from Explanatory Sentence 5)\\nI: Better results than monotherapy occur (from Explanatory Sentence 6)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patients have V600E mutation, Patients receive treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Rapid recovery of MAPK pathway signaling occurs, Resistance to BRAF inhibitors occurs)\\n--------\\nImplies(E, Not(C))\\nImplies(MEK inhibitors help prevent rapid recovery of MAPK pathway signaling, Not(Rapid recovery of MAPK pathway signaling occurs))\\n--------\\nImplies(F, G)\\nImplies(Combination therapies  are more effective in overcoming resistance, Better treatment outcomes occur)\\n--------\\nImplies(F, H)\\nImplies(Combination therapies  are more effective in overcoming resistance, Better clinical outcomes occur)\\n--------\\nImplies(H, I)\\nImplies(Better clinical outcomes occur, Better results than monotherapy occur)\\n--------\\n\\nDerived Implications:\\nImplies(Not(I), Not(F))\\nImplies(Not(Better results than monotherapy occur), Not(Combination therapies  are more effective in overcoming resistance))\\n--------\\nImplies(F, I)\\nImplies(Combination therapies  are more effective in overcoming resistance, Better results than monotherapy occur)\\n--------\\n'}",
            "6 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(H, I), Implies(Combination therapies are used, Better results than monotherapy are achieved) *)\\n(* H is from explanatory sentence 4, I is from explanatory sentence 4. *)\\n(* We already have Combination x, so we can infer BetterResults e. *)\\nthen have \"BetterResults e\" sledgehammer', 'solving time': 103.3210289478302, 'proof tactics': [], 'code': 'theory clinical_95_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patients :: \"entity \u21d2 bool\"\\n  V600EMutation :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  MAPKPathwaySignaling :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  BRAFInhibitors :: \"entity \u21d2 bool\"\\n  Associated :: \"event \u21d2 bool\"\\n  MEKInhibitors :: \"entity \u21d2 bool\"\\n  Help :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  CombinationTherapies :: \"entity \u21d2 bool\"\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Monotherapy :: \"entity \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Leads :: \"event \u21d2 bool\"\\n  BetterResults :: \"event \u21d2 bool\"\\n  Than :: \"event \u21d2 entity \u21d2 bool\"\\n  ClinicalOutcomes :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n  Results :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Patients with V600E mutation could receive treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. Patients x \u2227 V600EMutation x \u2227 Treatment y \u2227 Vemurafenib y \u2227 Receive e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 2: Rapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. Recovery x \u2227 MAPKPathwaySignaling x \u2227 Resistance y \u2227 BRAFInhibitors y \u2227 Associated e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 3: MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. MEKInhibitors x \u2227 Recovery y \u2227 MAPKPathwaySignaling y \u2227 Resistance z \u2227 BRAFInhibitors z \u2227 Help e1 \u2227 Agent e1 x \u2227 Prevent e2 \u2227 Patient e2 y \u2227 Overcome e2 \u2227 Patient e2 z\"\\n\\n(* Explanation 4: Combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than monotherapy, and this effectiveness directly leads to better results than monotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. CombinationTherapies x \u2227 Vemurafenib y \u2227 MEKInhibitor y \u2227 Resistance z \u2227 Monotherapy z \u2227 Effective e1 \u2227 Agent e1 x \u2227 Overcome e1 \u2227 Patient e1 z \u2227 Leads e2 \u2227 Agent e2 x \u2227 BetterResults e2 \u2227 Than e2 z\"\\n\\n(* Explanation 5: Better clinical outcomes from combination therapies often yield better results than monotherapy. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e. ClinicalOutcomes x \u2227 CombinationTherapies y \u2227 Monotherapy z \u2227 Yield e \u2227 Agent e x \u2227 BetterResults e \u2227 Than e z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\"\\n  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)\\n  shows \"\u2203x y z e. Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Yield e \u2227 Agent e x \u2227 Results e \u2227 BetterResults e \u2227 Than e y\"\\nproof -\\n  (* From the premise, we have known information about the combination, vemurafenib, and MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\" <ATP>\\n  (* There is a logical relation Implies(H, I), Implies(Combination therapies are used, Better results than monotherapy are achieved) *)\\n  (* H is from explanatory sentence 4, I is from explanatory sentence 4. *)\\n  (* We already have Combination x, so we can infer BetterResults e. *)\\n  then have \"BetterResults e\" <ATP>\\n  (* There is a logical relation Implies(I, J), Implies(Better results than monotherapy are achieved, Better clinical outcomes are achieved) *)\\n  (* I is from explanatory sentence 4, J is from explanatory sentence 5. *)\\n  (* We already have BetterResults e, so we can infer Better clinical outcomes are achieved. *)\\n  then have \"Yield e \u2227 Agent e x \u2227 Results e \u2227 BetterResults e \u2227 Than e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patients have V600E mutation (from Explanatory Sentence 1)\\nB: Patients receive treatment with vemurafenib (from Explanatory Sentence 1)\\nC: Rapid recovery of MAPK pathway signaling occurs (from Explanatory Sentence 2)\\nD: Resistance to BRAF inhibitors occurs (from Explanatory Sentence 2)\\nE: MEK inhibitors are used (from Explanatory Sentence 3)\\nF: Rapid recovery of MAPK pathway signaling is prevented (from Explanatory Sentence 3)\\nG: Resistance to BRAF inhibitors is overcome (from Explanatory Sentence 3)\\nH: Combination therapies are used (from Explanatory Sentence 4)\\nI: Better results than monotherapy are achieved (from Explanatory Sentence 4)\\nJ: Better clinical outcomes are achieved (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patients have V600E mutation, Patients receive treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Rapid recovery of MAPK pathway signaling occurs, Resistance to BRAF inhibitors occurs)\\n--------\\nImplies(E, F)\\nImplies(MEK inhibitors are used, Rapid recovery of MAPK pathway signaling is prevented)\\n--------\\nImplies(F, G)\\nImplies(Rapid recovery of MAPK pathway signaling is prevented, Resistance to BRAF inhibitors is overcome)\\n--------\\nImplies(H, I)\\nImplies(Combination therapies are used, Better results than monotherapy are achieved)\\n--------\\nImplies(I, J)\\nImplies(Better results than monotherapy are achieved, Better clinical outcomes are achieved)\\n--------\\n\\nDerived Implications:\\nImplies(E, G)\\nImplies(MEK inhibitors are used, Resistance to BRAF inhibitors is overcome)\\n--------\\nImplies(Not(J), Not(H))\\nImplies(Not(Better clinical outcomes are achieved), Not(Combination therapies are used))\\n--------\\nImplies(H, J)\\nImplies(Combination therapies are used, Better clinical outcomes are achieved)\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(Resistance to BRAF inhibitors is overcome), Not(MEK inhibitors are used))\\n--------\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_95_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patients :: \"entity \u21d2 bool\"\\n  V600EMutation :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  MAPKPathwaySignaling :: \"entity \u21d2 bool\"\\n  Rapid :: \"entity \u21d2 bool\"\\n  Associated :: \"event \u21d2 bool\"\\n  Resistance :: \"event \u21d2 bool\"\\n  BRAFInhibitors :: \"entity \u21d2 bool\"\\n  MEKInhibitors :: \"entity \u21d2 bool\"\\n  Help :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Overcoming :: \"event \u21d2 bool\"\\n  CombinationTherapies :: \"entity \u21d2 bool\"\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Than :: \"event \u21d2 entity \u21d2 bool\"\\n  VemurafenibMonotherapy :: \"entity \u21d2 bool\"\\n  Leads :: \"event \u21d2 bool\"\\n  Effectiveness :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  BetterResults :: \"event \u21d2 bool\"\\n  ClinicalOutcomes :: \"entity \u21d2 bool\"\\n  Better :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  Monotherapy :: \"entity \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n  Results :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Patients with V600E mutation could receive treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Patients x \u2227 V600EMutation y \u2227 Treatment z \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Patient e z \u2227 With z y\"\\n\\n(* Explanation 2: Rapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. Recovery x \u2227 MAPKPathwaySignaling y \u2227 Rapid x \u2227 Associated e \u2227 Agent e x \u2227 Resistance e \u2227 BRAFInhibitors y\"\\n\\n(* Explanation 3: MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. MEKInhibitors x \u2227 Recovery y \u2227 MAPKPathwaySignaling z \u2227 Rapid y \u2227 Help e1 \u2227 Agent e1 x \u2227 Prevent e2 \u2227 Patient e2 y \u2227 Overcoming e2 \u2227 Resistance e2 \u2227 BRAFInhibitors z\"\\n\\n(* Explanation 4: Combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than vemurafenib monotherapy, and this effectiveness directly leads to better results than monotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. CombinationTherapies x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Effective e1 \u2227 Agent e1 x \u2227 Overcoming e1 \u2227 Resistance e1 \u2227 (\u2203v. VemurafenibMonotherapy v \u2227 Than e1 v) \u2227 Leads e2 \u2227 Effectiveness e2 \u2227 Directly e2 \u2227 BetterResults e2 \u2227 (\u2203m. Monotherapy m \u2227 Than e2 m)\"\\n\\n(* Explanation 5: Better clinical outcomes from combination therapies often yield better results than monotherapy. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y e. ClinicalOutcomes x \u2227 CombinationTherapies y \u2227 Better x \u2227 Yield e \u2227 Agent e x \u2227 BetterResults e \u2227 (\u2203m. Monotherapy m \u2227 Than e m)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\"\\n  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)\\n  shows \"\u2203x y z e. Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Yield e \u2227 Agent e x \u2227 Results e \u2227 BetterResults e \u2227 (\u2203v. VemurafenibMonotherapy v \u2227 Than e v)\"\\nproof -\\n  (* From the premise, we have known information about the combination of vemurafenib and a MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\" <ATP>\\n  (* There is a logical relation Implies(F, G), Implies(Combination therapies are used, Better clinical outcomes are achieved) *)\\n  (* F is from explanatory sentence 4, G is from explanatory sentence 5. *)\\n  (* We already have Combination x, so we can infer Better clinical outcomes are achieved. *)\\n  then have \"BetterResults e\" <ATP>\\n  (* Explanation 5 states that better clinical outcomes from combination therapies often yield better results than monotherapy. *)\\n  (* We can use this to infer the hypothesis. *)\\n  then have \"Yield e \u2227 Agent e x \u2227 Results e \u2227 BetterResults e \u2227 (\u2203v. VemurafenibMonotherapy v \u2227 Than e v)\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patients have V600E mutation (from Explanatory Sentence 1)\\nB: Patients receive treatment with vemurafenib (from Explanatory Sentence 1)\\nC: Rapid recovery of MAPK pathway signaling occurs (from Explanatory Sentence 2)\\nD: Resistance to BRAF inhibitors occurs (from Explanatory Sentence 2)\\nE: MEK inhibitors are used (from Explanatory Sentence 3)\\nF: Combination therapies are used (from Explanatory Sentence 4)\\nG: Better clinical outcomes are achieved (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patients have V600E mutation, Patients receive treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Rapid recovery of MAPK pathway signaling occurs, Resistance to BRAF inhibitors occurs)\\n--------\\nImplies(E, Not(C))\\nImplies(MEK inhibitors are used, Not(Rapid recovery of MAPK pathway signaling occurs))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(Rapid recovery of MAPK pathway signaling occurs), Not(Resistance to BRAF inhibitors occurs))\\n--------\\nImplies(F, Not(D))\\nImplies(Combination therapies are used, Not(Resistance to BRAF inhibitors occurs))\\n--------\\nImplies(F, G)\\nImplies(Combination therapies are used, Better clinical outcomes are achieved)\\n--------\\n\\nDerived Implications:\\nImplies(E, Not(D))\\nImplies(MEK inhibitors are used, Not(Resistance to BRAF inhibitors occurs))\\n--------\\nImplies(F, Not(C))\\nImplies(Combination therapies are used, Not(Rapid recovery of MAPK pathway signaling occurs))\\n--------\\nImplies(D, Not(E))\\nImplies(Resistance to BRAF inhibitors occurs, Not(MEK inhibitors are used))\\n--------\\nImplies(C, Not(F))\\nImplies(Rapid recovery of MAPK pathway signaling occurs, Not(Combination therapies are used))\\n--------\\n'}",
            "8 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(F, G), Implies(Combination therapies are used, Better clinical outcomes are achieved) *)\\n(* F is from explanatory sentence 4, G is from explanatory sentence 5. *)\\n(* We already have Combination x, so we can infer Better clinical outcomes are achieved. *)\\nthen have \"BetterResults y\" sledgehammer', 'solving time': 103.41027522087097, 'proof tactics': [], 'code': 'theory clinical_95_8\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patients :: \"entity \u21d2 bool\"\\n  V600EMutation :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  MAPKPathwaySignaling :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  BRAFInhibitors :: \"entity \u21d2 bool\"\\n  AssociatedWith :: \"entity \u21d2 entity \u21d2 bool\"\\n  MEKInhibitors :: \"entity \u21d2 bool\"\\n  Help :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  CombinationTherapies :: \"entity \u21d2 bool\"\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Monotherapy :: \"entity \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Than :: \"entity \u21d2 entity \u21d2 bool\"\\n  Effectiveness :: \"event \u21d2 bool\"\\n  Leads :: \"event \u21d2 bool\"\\n  BetterResults :: \"entity \u21d2 bool\"\\n  ClinicalOutcomes :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  From :: \"entity \u21d2 entity \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patients with V600E mutation could receive treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Patients x \u2227 V600EMutation x \u2227 Treatment y \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Patient e y \u2227 With y z\"\\n\\n(* Explanation 2: Rapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. Recovery x \u2227 MAPKPathwaySignaling x \u2227 Resistance y \u2227 BRAFInhibitors y \u2227 AssociatedWith x y\"\\n\\n(* Explanation 3: MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2 e3. MEKInhibitors x \u2227 Recovery y \u2227 MAPKPathwaySignaling y \u2227 Resistance z \u2227 BRAFInhibitors z \u2227 Help e1 \u2227 Agent e1 x \u2227 Prevent e2 \u2227 Patient e2 y \u2227 Overcome e3 \u2227 Agent e3 z\"\\n\\n(* Explanation 4: Combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than vemurafenib monotherapy, and this effectiveness directly leads to better results than monotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2 e3. CombinationTherapies x \u2227 Vemurafenib y \u2227 MEKInhibitor y \u2227 Resistance z \u2227 Monotherapy w \u2227 Effective e1 \u2227 Agent e1 x \u2227 Overcome e3 \u2227 Agent e3 z \u2227 Than y w \u2227 Effectiveness e2 \u2227 Leads e2 \u2227 Agent e2 x \u2227 BetterResults y \u2227 Than y w\"\\n\\n(* Explanation 5: Better clinical outcomes from combination therapies often yield better results than monotherapy. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e. ClinicalOutcomes x \u2227 CombinationTherapies y \u2227 BetterResults z \u2227 Monotherapy w \u2227 Yield e \u2227 Agent e x \u2227 Patient e z \u2227 From x y \u2227 Than z w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor y\"\\n  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)\\n  shows \"\u2203x y e. Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor y \u2227 Yield e \u2227 Agent e x \u2227 Patient e y \u2227 BetterResults y \u2227 Monotherapy z \u2227 Than y z\"\\nproof -\\n  (* From the premise, we have known information about the combination, vemurafenib, and MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor y\" <ATP>\\n  (* There is a logical relation Implies(F, G), Implies(Combination therapies are used, Better clinical outcomes are achieved) *)\\n  (* F is from explanatory sentence 4, G is from explanatory sentence 5. *)\\n  (* We already have Combination x, so we can infer Better clinical outcomes are achieved. *)\\n  then have \"BetterResults y\" <ATP>\\n  (* Explanation 5 states that better clinical outcomes from combination therapies often yield better results than monotherapy. *)\\n  (* We can use this to infer the hypothesis. *)\\n  then have \"Yield e \u2227 Agent e x \u2227 Patient e y \u2227 Monotherapy z \u2227 Than y z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patients have V600E mutation (from Explanatory Sentence 1)\\nB: Patients receive treatment with vemurafenib (from Explanatory Sentence 1)\\nC: Rapid recovery of MAPK pathway signaling occurs (from Explanatory Sentence 2)\\nD: Resistance to BRAF inhibitors occurs (from Explanatory Sentence 2)\\nE: MEK inhibitors are used (from Explanatory Sentence 3)\\nF: Combination therapies are used (from Explanatory Sentence 4)\\nG: Better clinical outcomes are achieved (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patients have V600E mutation, Patients receive treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Rapid recovery of MAPK pathway signaling occurs, Resistance to BRAF inhibitors occurs)\\n--------\\nImplies(E, Not(C))\\nImplies(MEK inhibitors are used, Not(Rapid recovery of MAPK pathway signaling occurs))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(Rapid recovery of MAPK pathway signaling occurs), Not(Resistance to BRAF inhibitors occurs))\\n--------\\nImplies(F, Not(D))\\nImplies(Combination therapies are used, Not(Resistance to BRAF inhibitors occurs))\\n--------\\nImplies(F, G)\\nImplies(Combination therapies are used, Better clinical outcomes are achieved)\\n--------\\n\\nDerived Implications:\\nImplies(E, Not(D))\\nImplies(MEK inhibitors are used, Not(Resistance to BRAF inhibitors occurs))\\n--------\\nImplies(F, Not(C))\\nImplies(Combination therapies are used, Not(Rapid recovery of MAPK pathway signaling occurs))\\n--------\\nImplies(D, Not(E))\\nImplies(Resistance to BRAF inhibitors occurs, Not(MEK inhibitors are used))\\n--------\\nImplies(C, Not(F))\\nImplies(Rapid recovery of MAPK pathway signaling occurs, Not(Combination therapies are used))\\n--------\\n'}",
            "9 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(F, H), Implies(Combination therapies are used, Better results than monotherapy are achieved) *)\\n(* F is from explanatory sentence 4, H is from explanatory sentence 5. *)\\n(* Since we have Combination x, we can infer Better results than monotherapy are achieved. *)\\nthen have \"Yield e \u2227 Agent e x \u2227 Results e \u2227 BetterResults e \u2227 Than e y\" sledgehammer', 'solving time': 103.40648126602173, 'proof tactics': [], 'code': 'theory clinical_95_9\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patients :: \"entity \u21d2 bool\"\\n  V600EMutation :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"event \u21d2 entity \u21d2 bool\"\\n  Recovery :: \"entity \u21d2 bool\"\\n  MAPKPathway :: \"entity \u21d2 bool\"\\n  Signaling :: \"entity \u21d2 bool\"\\n  Associated :: \"event \u21d2 bool\"\\n  Resistance :: \"event \u21d2 bool\"\\n  BRAFInhibitors :: \"event \u21d2 bool\"\\n  MEKInhibitors :: \"entity \u21d2 bool\"\\n  Help :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Overcoming :: \"event \u21d2 bool\"\\n  CombinationTherapies :: \"entity \u21d2 bool\"\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Than :: \"event \u21d2 entity \u21d2 bool\"\\n  Leads :: \"event \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  ClinicalOutcomes :: \"entity \u21d2 bool\"\\n  BetterOutcomes :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  Results :: \"event \u21d2 bool\"\\n  BetterResults :: \"event \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patients with V600E mutation could receive treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Patients x \u2227 V600EMutation y \u2227 Treatment z \u2227 Vemurafenib z \u2227 Receive e \u2227 Agent e x \u2227 Patient e z \u2227 With e z\"\\n\\n(* Explanation 2: Rapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. Recovery x \u2227 MAPKPathway y \u2227 Signaling y \u2227 Associated e \u2227 Agent e x \u2227 Resistance e \u2227 BRAFInhibitors e\"\\n\\n(* Explanation 3: MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. MEKInhibitors x \u2227 Recovery y \u2227 MAPKPathway z \u2227 Signaling z \u2227 Help e1 \u2227 Agent e1 x \u2227 Prevent e2 \u2227 Patient e2 y \u2227 Overcoming e2 \u2227 Resistance e2 \u2227 BRAFInhibitors e2\"\\n\\n(* Explanation 4: Combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than vemurafenib monotherapy, and this effectiveness directly leads to better clinical outcomes. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2 c. CombinationTherapies x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Effective e1 \u2227 Agent e1 x \u2227 Overcoming e1 \u2227 Resistance e1 \u2227 Than e1 y \u2227 Leads e2 \u2227 Effectiveness e2 \u2227 Directly e2 \u2227 ClinicalOutcomes c \u2227 BetterOutcomes c\"\\n\\n(* Explanation 5: Better clinical outcomes from combination therapies often yield better results than monotherapy. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y e. ClinicalOutcomes x \u2227 CombinationTherapies y \u2227 BetterOutcomes x \u2227 Yield e \u2227 Agent e x \u2227 Results e \u2227 BetterResults e \u2227 Than e y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\"\\n  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)\\n  shows \"\u2203x y z e. Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Yield e \u2227 Agent e x \u2227 Results e \u2227 BetterResults e \u2227 Than e y\"\\nproof -\\n  (* From the assumption, we have known information about the combination of vemurafenib and a MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\" <ATP>\\n  (* There is a logical relation Implies(F, H), Implies(Combination therapies are used, Better results than monotherapy are achieved) *)\\n  (* F is from explanatory sentence 4, H is from explanatory sentence 5. *)\\n  (* Since we have Combination x, we can infer Better results than monotherapy are achieved. *)\\n  then have \"Yield e \u2227 Agent e x \u2227 Results e \u2227 BetterResults e \u2227 Than e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patients have V600E mutation (from Explanatory Sentence 1)\\nB: Patients receive treatment with vemurafenib (from Explanatory Sentence 1)\\nC: Rapid recovery of MAPK pathway signaling occurs (from Explanatory Sentence 2)\\nD: Resistance to BRAF inhibitors occurs (from Explanatory Sentence 2)\\nE: MEK inhibitors are used (from Explanatory Sentence 3)\\nF: Combination therapies are used (from Explanatory Sentence 4)\\nG: Better clinical outcomes are achieved (from Explanatory Sentence 4)\\nH: Better results than monotherapy are achieved (from Explanatory Sentence 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patients have V600E mutation, Patients receive treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Rapid recovery of MAPK pathway signaling occurs, Resistance to BRAF inhibitors occurs)\\n--------\\nImplies(E, Not(C))\\nImplies(MEK inhibitors are used, Not(Rapid recovery of MAPK pathway signaling occurs))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(Rapid recovery of MAPK pathway signaling occurs), Not(Resistance to BRAF inhibitors occurs))\\n--------\\nImplies(F, And(Not(D), G))\\nImplies(Combination therapies are used, G & ~D)\\n--------\\nImplies(G, H)\\nImplies(Better clinical outcomes are achieved, Better results than monotherapy are achieved)\\n--------\\n\\nDerived Implications:\\nImplies(D, Not(F))\\nImplies(Resistance to BRAF inhibitors occurs, Not(Combination therapies are used))\\n--------\\nImplies(Not(G), Not(F))\\nImplies(Not(Better clinical outcomes are achieved), Not(Combination therapies are used))\\n--------\\nImplies(E, Not(D))\\nImplies(MEK inhibitors are used, Not(Resistance to BRAF inhibitors occurs))\\n--------\\nImplies(D, Not(E))\\nImplies(Resistance to BRAF inhibitors occurs, Not(MEK inhibitors are used))\\n--------\\nImplies(F, H)\\nImplies(Combination therapies are used, Better results than monotherapy are achieved)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(Better results than monotherapy are achieved), Not(Combination therapies are used))\\n--------\\nImplies(F, G)\\nImplies(Combination therapies are used, Better clinical outcomes are achieved)\\n--------\\nImplies(F, Not(D))\\nImplies(Combination therapies are used, Not(Resistance to BRAF inhibitors occurs))\\n--------\\nImplies(F, Not(C))\\nImplies(Combination therapies are used, Not(Rapid recovery of MAPK pathway signaling occurs))\\n--------\\nImplies(C, Not(F))\\nImplies(Rapid recovery of MAPK pathway signaling occurs, Not(Combination therapies are used))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(F, H), Implies(Combination therapies are used, Better results than monotherapy are achieved) *)\\n(* F is from explanatory sentence 4, H is from explanatory sentence 4 and 5. *)\\n(* Since we have Combination x, we can infer BetterResults y. *)\\nthen have \"BetterResults y\" sledgehammer', 'solving time': 103.29327082633972, 'proof tactics': [], 'code': 'theory clinical_95_10\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Patients :: \"entity \u21d2 bool\"\\n  V600EMutation :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Receive :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n  RapidRecovery :: \"entity \u21d2 bool\"\\n  MAPKPathway :: \"entity \u21d2 bool\"\\n  Associated :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  BRAFInhibitors :: \"entity \u21d2 bool\"\\n  MEKInhibitors :: \"entity \u21d2 bool\"\\n  Help :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Overcoming :: \"event \u21d2 entity \u21d2 bool\"\\n  CombinationTherapies :: \"entity \u21d2 bool\"\\n  Vemurafenib :: \"entity \u21d2 bool\"\\n  MEKInhibitor :: \"entity \u21d2 bool\"\\n  Effective :: \"event \u21d2 bool\"\\n  Monotherapy :: \"entity \u21d2 bool\"\\n  Than :: \"entity \u21d2 entity \u21d2 bool\"\\n  Effectiveness :: \"entity \u21d2 bool\"\\n  Leads :: \"event \u21d2 bool\"\\n  ClinicalOutcomes :: \"entity \u21d2 bool\"\\n  BetterResults :: \"entity \u21d2 bool\"\\n  Yield :: \"event \u21d2 bool\"\\n  Combination :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Patients with V600E mutation could receive treatment with vemurafenib. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Patients x \u2227 V600EMutation y \u2227 Treatment z \u2227 Receive e \u2227 Agent e x \u2227 Patient e z \u2227 With z y\"\\n\\n(* Explanation 2: Rapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. RapidRecovery x \u2227 MAPKPathway y \u2227 Associated x y \u2227 Resistance y \u2227 BRAFInhibitors y\"\\n\\n(* Explanation 3: MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. MEKInhibitors x \u2227 RapidRecovery y \u2227 MAPKPathway z \u2227 Help e1 \u2227 Agent e1 x \u2227 Prevent e2 \u2227 Patient e2 y \u2227 Overcoming e2 z \u2227 Resistance z \u2227 BRAFInhibitors z\"\\n\\n(* Explanation 4: Combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than vemurafenib monotherapy, and this effectiveness directly leads to better clinical outcomes and better results than monotherapy. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2. CombinationTherapies x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Effective e1 \u2227 Agent e1 x \u2227 Overcoming e1 y \u2227 Resistance y \u2227 Monotherapy z \u2227 Than y z \u2227 Effectiveness w \u2227 Leads e2 \u2227 Agent e2 w \u2227 ClinicalOutcomes y \u2227 BetterResults y \u2227 Than y z\"\\n\\n(* Explanation 5: Better clinical outcomes from combination therapies often yield better results than monotherapy. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e. ClinicalOutcomes x \u2227 CombinationTherapies y \u2227 Yield e \u2227 Agent e x \u2227 BetterResults y \u2227 Monotherapy z \u2227 Than y z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\"\\n  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy *)\\n  shows \"\u2203x y z e. Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z \u2227 Yield e \u2227 Agent e x \u2227 Patient e y \u2227 BetterResults y \u2227 Monotherapy z \u2227 Than y z\"\\nproof -\\n  (* From the premise, we have known information about the combination, vemurafenib, and MEK inhibitor. *)\\n  from asm have \"Combination x \u2227 Vemurafenib y \u2227 MEKInhibitor z\" <ATP>\\n  (* There is a logical relation Implies(F, H), Implies(Combination therapies are used, Better results than monotherapy are achieved) *)\\n  (* F is from explanatory sentence 4, H is from explanatory sentence 4 and 5. *)\\n  (* Since we have Combination x, we can infer BetterResults y. *)\\n  then have \"BetterResults y\" <ATP>\\n  (* We also have the logical relation Implies(F, G), Implies(Combination therapies are used, Better clinical outcomes are achieved) *)\\n  (* Since we have Combination x, we can infer Better clinical outcomes are achieved, which implies BetterResults y. *)\\n  then have \"Yield e \u2227 Agent e x \u2227 Patient e y \u2227 Monotherapy z \u2227 Than y z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Patients have V600E mutation (from Explanatory Sentence 1)\\nB: Patients receive treatment with vemurafenib (from Explanatory Sentence 1)\\nC: Rapid recovery of MAPK pathway signaling occurs (from Explanatory Sentence 2)\\nD: Resistance to BRAF inhibitors occurs (from Explanatory Sentence 2)\\nE: MEK inhibitors are used (from Explanatory Sentence 3)\\nF: Combination therapies are used (from Explanatory Sentence 4)\\nG: Better clinical outcomes are achieved (from Explanatory Sentence 4 and 5)\\nH: Better results than monotherapy are achieved (from Explanatory Sentence 4 and 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Patients have V600E mutation, Patients receive treatment with vemurafenib)\\n--------\\nImplies(C, D)\\nImplies(Rapid recovery of MAPK pathway signaling occurs, Resistance to BRAF inhibitors occurs)\\n--------\\nImplies(E, Not(C))\\nImplies(MEK inhibitors are used, Not(Rapid recovery of MAPK pathway signaling occurs))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(Rapid recovery of MAPK pathway signaling occurs), Not(Resistance to BRAF inhibitors occurs))\\n--------\\nImplies(F, And(G, H))\\nImplies(Combination therapies are used, G & H)\\n--------\\nImplies(G, H)\\nImplies(Better clinical outcomes are achieved, Better results than monotherapy are achieved)\\n--------\\n\\nDerived Implications:\\nImplies(Not(G), Not(F))\\nImplies(Not(Better clinical outcomes are achieved), Not(Combination therapies are used))\\n--------\\nImplies(E, Not(D))\\nImplies(MEK inhibitors are used, Not(Resistance to BRAF inhibitors occurs))\\n--------\\nImplies(D, Not(E))\\nImplies(Resistance to BRAF inhibitors occurs, Not(MEK inhibitors are used))\\n--------\\nImplies(F, H)\\nImplies(Combination therapies are used, Better results than monotherapy are achieved)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(Better results than monotherapy are achieved), Not(Combination therapies are used))\\n--------\\nImplies(F, G)\\nImplies(Combination therapies are used, Better clinical outcomes are achieved)\\n--------\\n'}"
        ]
    }
}